Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

Novo Nordisk hit by slowing Ozempic sales, Tesla shareholders sue Musk over Robotaxi - Stock market news and latest business ...

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

Novo Nordisk has called on the US regulator to ban imports of a key ingredient used to make copycat versions of its obesity and diabetes drugs, as the Danish drugmaker loses market share to the ...

Novo Nordisk faces a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to intense competition ...

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.